Newsroom | 97126 results

LONDRA--(BUSINESS WIRE)--Prokarium, società biofarmaceutica in fase clinica all'avanguardia nelle immunoterapie batteriche per il trattamento dei tumori solidi, oggi ha annunciato i risultati in termini di sicurezza ed efficacia antitumorale di una revisione intermedia dello studio PARADIGM-1 di fase 1/1b su ZH9, in corso di svolgimento, nei pazienti affetti da tumori vescicali non muscolo-invasivi (NMIBC). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la version...

LONDEN--(BUSINESS WIRE)--Prokarium, een biofarmaceutisch bedrijf in klinische fase dat pionierswerk verricht in bacteriële immunotherapieën voor de behandeling van vaste tumoren, maakte vandaag de resultaten bekend over de veiligheid en doeltreffendheid bij de bestrijding van tumoren uit een tussentijdse beoordeling van de lopende Fase 1/1b PARADIGM-1 studie van ZH9 bij NMIBC-patiënten (non-muscle invasive bladder cancer = niet-spierinvasieve blaaskanker). Deze bekendmaking is officieel geldend...

LONDRES--(BUSINESS WIRE)--  Prokarium annonce des résultats intermédiaires positifs de l’essai de phase 1/1b PARADIGM-1 évaluant ZH9 chez des patients atteints d’un cancer de la vessie non invasif sur le plan musculaire, avec une excellente tolérance et une efficacité précoce encourageante   Prokarium, société biopharmaceutique au stade clinique pionnière dans les immunothérapies bactériennes pour le traitement des tumeurs solides, a annoncé aujourd’hui des résultats de sécurité et d’efficacité...

LONDRES--(BUSINESS WIRE)--Prokarium, una empresa biofarmacéutica en fase clínica pionera en inmunoterapias bacterianas para el tratamiento de tumores sólidos, anunció hoy los resultados de seguridad y eficacia antitumoral de una revisión interina del ensayo PARADIGM-1 fase 1/1b en curso de ZH9 en pacientes con cáncer de vejiga sin invasión muscular (NMIBC). El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá s...

LONDON--(BUSINESS WIRE)--Prokarium, ein biopharmazeutisches Unternehmen im klinischen Stadium, das Pionierarbeit bei bakteriellen Immuntherapien zur Behandlung solider Tumoren leistet, gab heute die Ergebnisse zur Sicherheit und Antitumorwirksamkeit aus einer Zwischenauswertung der laufenden Phase-1/1b-Studie PARADIGM-1 mit ZH9 bei Patienten mit nicht-muskelinvasivem Blasenkrebs (NMIBC) bekannt. Diese Daten wurden im Rahmen eines mündlichen Vortrags auf der Jahrestagung der American Urological...

CAMBRIDGE, England--(BUSINESS WIRE)--OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced it has been selected to receive a Discovery Award from the Longitude Prize on ALS. The award grants OutSee access to genomic data from 9,000 amyotrophic lateral sclerosis (ALS) patients, in addition to £100k in funding, supporting a research project to uncover novel therapeutic targets for ALS using OutSee’s proprietary...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT’S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is based on positive results from the global, pivotal Phase III OC...

GHENT, Belgium & MARCHE-EN-FAMENNE, Belgium--(BUSINESS WIRE)--ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. Mark Throsby has served as Executive Chairm...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago. "Genentech’s ASCO data reflect our commitment to addressing those cancers that impose the highest burden on patients and society," said Levi Garraway, M.D., Ph.D., chief medi...

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Of...